Every year at our annual Forbes Healthcare Summit, I feel like I cram a month's worth of reporting into a day-and-a-half. Many Forbes writes have already weighed in, as have outside organizations like Bloomberg, Gawker and Business Insider. I'm still recovering and formulating my own thoughts. But for all of you who couldn't be there, here are the first video clips from the day. Keep in mind: these are just snapshots of what was a 10-hour-plus discussion about cost, value, data openness and innovation. There will be more video from the day, and I'll have more to say. But here are some amazing moments.
How Should Pharma Spend Its R&D Money?
Their ideas are controversial to some.
Why
Ever since Pfizer announced plans to buy Allergan, Forbes contributor (and former Pfizer R&D chief) John LaMattina has worried about what will happen to the larger company's researchers. Here, Allergan CEO Brent Saunders responds to LaMattina's questions.
Martin Shkreli On His View Of Fiduciary Responsibility
You've probably already read about this.
Martin Shkreli: 'I Would've Raised Prices Higher'
It's even more likely you read about this.
Martin Shkreli Questioned By Express Scripts’ Chief Medical Officer
When Shkreli said that Express Scripts had originally been supportive of his price-increasing strategy,
Pfizer CEO: 'What We're Doing May Fundamentally Save The Industry'
Isn't avoiding U.S. taxes by buying Allergan bad for Pharma's image? Pfizer CEO Ian Read says he thinks he may be saving U.S. pharma, not harming it.
Amid Controversy, Theranos Sees Highest Volume Ever
Theranos has been beset by controversy. But founder Elizabeth Holmes says sales are up.
Elizabeth Holmes: 'I Actually Don't Think Our Valuation Is What Matters Here'
How can Theranos be worth $10 billion? I asked. Here is Holmes' answer.
